Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,858.00
Bid: 6,847.00
Ask: 6,850.00
Change: 1.00 (0.01%)
Spread: 3.00 (0.04%)
Open: 6,800.00
High: 6,921.00
Low: 6,779.00
Yest. Close: 6,857.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 2-Lloyds, Stan Chart weigh on FTSE 100 amid global stocks rout; AstraZeneca gains

(For a live blog on European stocks, type LIVE/ in an Eikon news window)* Lloyds Bank slumps to eight-year low* Oil stocks extend losses to seventh straight session* AstraZeneca gains on topping profit, sales expectations* FTSE 100 down 2.3%, FTSE 2...

30 Jul 20 09:30

LONDON MARKET OPEN: FTSE 100 Slides; Lloyds Tumbles After Results

LONDON MARKET OPEN: FTSE 100 Slides; Lloyds Tumbles After Results

30 Jul 20 08:46

UPDATE 2-AstraZeneca tops estimates as coronavirus vaccine hopes persist

* Q2 profit and sales beat on portfolio strength* Reiterates 2020 guidance for what has been a strong year* Optimism around AZ/Oxford coronavirus vaccine high* Shares rise as much as 3% in morning trade (Writes through, adds details, context, shares...

30 Jul 20 07:57

UPDATE 3-"So far, so good" on leading COVID vaccine, says AstraZeneca

* Q2 profit and sales beat on portfolio strength* Reiterates 2020 guidance for what has been a strong year* Optimism around AZ/Oxford coronavirus vaccine high* Shares rise more than 3% in morning trade (Adds CEO quote from media call, updates shares...

30 Jul 20 07:57

LONDON MARKET PRE-OPEN: Shell, Lloyds Impairments; Astra Keeps Outlook

LONDON MARKET PRE-OPEN: Shell, Lloyds Impairments; Astra Keeps Outlook

30 Jul 20 07:43

AstraZeneca maintains guidance after first-half growth

(Sharecast News) - AstraZeneca reported a 12% rise in total revenue in its first half on Thursday, or 14% at constant exchange rates, to $12.63bn (£9.75bn), with growth across all three of its therapy areas and in all of its regions.

30 Jul 20 07:27

Thursday preview: US tech titans, AstraZeneca in focus

(Sharecast News) - The market spotlight will fall on earnings reports from several of the largest corporates in the States, as they update shareholders on their performance over the three months to June, including Amazon, Alphabet, Facebook, and Microsoft.

29 Jul 20 16:19

Wednesday broker round-up

(Sharecast News) - Sanne: RBC Capital Markets reiterates sector performer with a target price of 600.0p.

29 Jul 20 13:29

UK BROKER RATINGS SUMMARY: Berenberg Raises Carnival To Hold From Sell

UK BROKER RATINGS SUMMARY: Berenberg Raises Carnival To Hold From Sell

29 Jul 20 09:47

UPDATE 2-Britain secures 60 mln doses of Sanofi/GSK COVID-19 vaccine

* Britain secures fourth vaccine supply deal* Sanofi/GSK see regulatory approval possible in H1 2021* "No guarantees" in vaccine hunt, UK minister says* Britain decided against joining EU scheme* For FACTBOX on vaccine race, click on (Adds detail)By...

29 Jul 20 06:26

Germany's IDT warns against equipment price hike in scramble for COVID-19 vaccine

By Caroline Copley and Ludwig BurgerBERLIN/FRANKFURT, July 28 (Reuters) - A scramble to produce COVID-19 vaccines is pushing up prices for some bottling equipment and other raw materials, adding to industry concerns about limited output, a German ...

28 Jul 20 17:00

AstraZeneca upbeat on latest Farxiga trial results

(Sharecast News) - AstraZeneca said on Tuesday that high-level results from the phase 3 'DAPA-CKD- trial of 'Farxiga', or dapagliflozin, showed a "statistically significant and clinically meaningful" effect on its primary endpoint.

28 Jul 20 08:38

UPDATE 1-AstraZeneca's Farxiga meets chronic kidney disease trial main goal

(Adds details on the trial, background)July 28 (Reuters) - AstraZeneca Plc said on Tuesday its diabetes treatment Farxiga met the main goal in a late-stage trial testing the drug's effectiveness in treating patients with chronic kidney disease (CK...

28 Jul 20 07:31

UPDATE 2-AstraZeneca diabetes drug shows promise in severe kidney condition

* Farxiga meets all main goals of late-stage study* Rival from Eli Lilly yet to get FDA approval for similar setting* Farxiga already approved for type-2 diabetes, heart failure (Writes through, adds details on drug, context and shares)By Aakash B...

28 Jul 20 07:31

AstraZeneca's Farxiga meets chronic kidney disease trial main goal

July 28 (Reuters) - AstraZeneca Plc said on Tuesday its diabetes drug Farxiga met the main goal in a late-stage trial testing the drug's effectiveness in treating patients with chronic kidney disease.The trial also met all of its secondary goals i...

28 Jul 20 07:16

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.